🟢 Cue Biopharma is trading 6.6% up; immediate catalyst remains unclear

Cue Biopharma is trading at $23.81, up 6.63%, with no clear immediate catalyst identified for the October 9 move.

• No company-specific announcement explaining the move was found; available company news centers on earlier CUE-221 trial results.
• The biotech-sector context was negative, with XBI down 2.04%, and does not explain the gain.
• Major-index gains were modest and do not establish a broader-market cause; the evidence does not support attributing the move to the earlier trial news.